Kofi Asomaning, PhD, MD

Pfizer, Inc., New York, NY, USA

Poster(s):

• (260) Evaluation of Digital Data collection Methods in a Prospective Pregnancy Registry for a Migraine Product with Both Acute and Preventive Indications
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (273) Gabapentin in Pregnancy and Birth Outcomes: a Population-based Prevalence Study in Nordic Countries (EUPAS38620)
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (342) Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST